A typical HBOT course runs 40 sessions over 8 weeks — 5 days a week, Monday through Friday. The timeline of what you may feel is well-mapped for FDA-cleared wound-care uses. Off-label uses follow less predictable patterns.
This guide walks through what to expect week by week. It covers the FDA-cleared uses — diabetic foot, radiation injury, chronic bone infection — where the timeline is best-studied. It also covers what we know about off-label timelines. See the osteomyelitis evidence atlas for the full study-by-study evidence breakdown.
The honest framing: HBOT works on a slow clock. Most patients see no big change in week 1. The wound-bed work is happening, but it takes weeks to become visible.
Week 1 (sessions 1 to 5): adaptation phase
The first week is mostly about acclimating to the chamber and managing immediate side effects. Outcome changes are rare in week 1.
Common experiences in week 1: ear pain during compression (especially in session 1), post-session fatigue, anxiety about confinement, and learning the ear equalization technique. Most patients adapt by session 5.
Baseline measurements are typically taken in week 1. For FDA-cleared wound indications, transcutaneous oxygen (TcPO2) is measured at the wound bed pre-protocol. Cognitive measures are typically taken for off-label brain indications.
For more on the chamber experience, see our first session walkthrough. For ear technique, see our ear equalization guide.
Week 2 (sessions 6 to 10): early adaptation
By week 2, most patients have adapted to the chamber. Ear pain is rare. Post-session fatigue starts to lessen.
For diabetic foot ulcer patients, some early wound-bed changes may appear. Granulation tissue may begin to form in stalled wounds. Wound surface oxygen often shows modest improvement.
For radiation injury patients, week 2 is generally too early for visible change. The angiogenic process the protocol is driving takes longer to produce visible tissue effects.
For off-label patients (TBI, autism, athletic recovery), week 2 is typically the start of subjective change reports. Sleep quality may improve and energy may shift. Subjective measures are unreliable but worth tracking. See celebrity endorsements vs. the actual recovery evidence for the endorsement-by-endorsement evidence audit.
Week 3 (sessions 11 to 15): emerging change
Week 3 is often where the first real changes appear in FDA-cleared indications.
For diabetic foot ulcers, granulation tissue is typically established. Wound margins may start to contract. Surface oxygen on the wound bed often rises 25 to 50% over baseline (Faglia et al., Diabetes Care 1996).
For radiation tissue injury patients (especially radionecrosis after head and neck radiation), tissue softening and reduced inflammation may begin. Pain levels may drop modestly.
For off-label patients, week 3 is typically the high-watermark for subjective improvement reports. This is where placebo and expectation effects are strongest. Objective measures (validated cognitive tests, sleep tracking data) are more reliable than self-report at this stage.
Week 4 (sessions 16 to 20): re-evaluation point
The 20-session mark is the standard re-evaluation point per the UHMS Indications Manual 2023. Most clinics re-check at this point.
For wound-care patients, the re-check includes TcPO2 measurement and wound photos. Patients who show no wound-bed change at this point are unlikely to benefit from more treatment.
For off-label patients, the 20-session mark is a reasonable point to consider stopping if no objective changes show up. Sunk-cost bias often pushes patients past this point — be aware of it.
This is the right point to discuss whether to continue with your clinic. A reasonable clinic will be honest about whether the data supports continuing.
Week 5 (sessions 21 to 25): mature change
By week 5, wound-care patients who are responding typically show clear mature granulation, contracting wound margins, and rising TcPO2 values (Hopf et al., Wound Repair Regen 2005).
For radiation patients, soft tissue softening is generally visible. Pain levels often drop substantially. Functional improvement — jaw mobility, swallowing, voice quality after head and neck radiation — may appear (Marx, Oral Surg 1983).
For off-label patients, week 5 is where the placebo effect typically peaks. Subjective improvement reports are often strongest here. Objective measures should be taken at this point and compared to baseline.
Week 6 (sessions 26 to 30): consolidation
The middle-to-late phase of the protocol focuses on consolidating gains. Wound margins continue to contract. Granulation tissue matures into stronger tissue.
For radiation patients, this is typically where dental procedures (extractions, implants) can be safely planned after head and neck radiation. The classic 30-pre/10-post protocol is designed around this window.
For off-label patients, the consolidation phase is where the placebo effect tends to plateau. Subjective improvement reports stabilize. Objective measures (when taken) should show stable values relative to week 4 measurements.
Week 7 (sessions 31 to 35): preparing for completion
Week 7 is the protocol's late phase. Wound-care patients typically have substantial wound closure. Some patients see full closure here; others have stable, healing wounds that will close in the post-protocol period.
For radiation patients, the late phase often coincides with planned surgical procedures. The HBOT preparation is largely complete; the surgical work follows.
For off-label patients, week 7 marks the time to plan post-protocol care. If the protocol has produced measurable changes, continued lower-frequency HBOT may be considered. If no objective changes are detectable, the protocol is winding down without a clear next step.
Week 8 (sessions 36 to 40): protocol completion
The final sessions complete the protocol. Re-measurement of baseline indicators is standard.
For wound-care patients, TcPO2 is re-measured. Wound documentation is updated. The patient is typically referred back to standard wound care for ongoing maintenance.
For radiation patients, post-protocol assessment focuses on whether planned procedures (extractions, reconstructions) can proceed safely. The HBOT preparation phase is complete.
For off-label patients, the post-protocol assessment is more variable. Some patients pursue maintenance HBOT (1 to 2 sessions per month) on the theory that the gains will dissipate without ongoing exposure. Maintenance HBOT is not well-studied.
Post-protocol period (weeks 9 to 24)
After protocol completion, several things happen.
Eye changes resolve. Most patients with HBOT-induced temporary myopia see vision return to baseline within 1 to 6 months. New eyeglass prescriptions should wait until post-protocol stabilization.
Wound consolidation. Wound-care patients typically continue to show improvement for 3 to 6 months after protocol completion. The vascular bed that HBOT helped build continues to support healing.
For radiation patients, the protective effect of the HBOT-induced vascularization persists for years. The exact duration varies.
For off-label patients, durability of any subjective gains is unpredictable. Some report sustained improvement; others report regression toward baseline within weeks to months.
What if you don't see progress
A reasonable framework. If you reach session 20 without measurable change on objective measures, the math for continuing is weak.
For wound-care patients, the UHMS Indications Manual 2023 recommends discontinuation if no progress is detectable at session 20. Continuing past this point is not supported by trial data.
For off-label patients, session 20 is a reasonable budget cutoff for trial protocols. Continuing past this point on the strength of subjective reports alone is not data-driven.
For more on managing expectations, see our HBOT common beginner mistakes guide.
How to track progress objectively
A practical checklist.
For wound-care: TcPO2 measurements, wound photographs, wound dimensions (length, width, depth), pain ratings.
For brain indications: validated cognitive tests (MoCA, BDI for depression, validated symptom scales), sleep tracking data, work or school performance metrics.
For athletic recovery: power output, sprint times, lift performance, perceived recovery ratings, sleep quality.
For anti-aging: cognitive testing, biomarker panels (if available), HRV measurements, sleep tracking.
In all cases, baseline measurements before session 1 are essential. Mid-protocol measurements at session 20 and post-protocol measurements after session 40 complete the data set.
Bottom line
HBOT works on a slow clock. The first week is adaptation, while weeks 2 to 4 show emerging change for FDA-cleared indications. The 20-session mark is the standard re-evaluation point.
Sessions 21 to 40 produce consolidation and mature outcomes. Post-protocol, gains continue for some indications (wound care) and may plateau or regress for others (off-label) (Tibbles & Edelsberg, NEJM 1996).
For any HBOT protocol, baseline measurements are essential. Mid-protocol re-evaluation at session 20 is standard. Sunk-cost bias is a real risk in HBOT — be willing to stop if data does not support continuing.
Related Reading
- HBOT 40-session protocol: why it became the standard
- HBOT frequency: daily, weekly, and maintenance protocols
- Your first HBOT session: full walkthrough
- HBOT common beginner mistakes
- HBOT side effects and safety: the real risk profile
Frequently asked questions
How long does it take to see HBOT results?
For FDA-cleared wound-care indications, most patients see measurable wound-bed changes between weeks 2 and 5. The standard re-evaluation point is session 20 (week 4).
Can I stop HBOT early if I see improvement?
Discuss with your physician. Standard protocols complete the full 40 sessions to build mature vascularization. Stopping early may reduce the durability of gains.
What if I see no progress at session 20?
The UHMS Indications Manual recommends re-evaluation at session 20. Lack of measurable progress at this point predicts limited benefit from continuing. Continuing past this point without progress is not data-supported.
Do HBOT results last after the protocol ends?
For wound-care indications, results typically last and continue to improve for months. For off-label indications, durability is unpredictable and varies between patients.
Should I do maintenance HBOT after a full protocol?
Maintenance HBOT (1 to 2 sessions per month) is offered by some clinics for off-label indications. The trial evidence for maintenance HBOT is limited.
Medical disclaimer: This guide is informational and does not constitute medical advice. HBOT carries real risks including ear injury, oxygen-related harm, and chamber fire. Discuss any HBOT plan with a doctor trained in hyperbaric medicine before starting. The FDA has cleared HBOT for 13 specific uses; uses outside that list are off-label.
-- The HBOT Finder Team